ArticleOncology letters2019
Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 48 citations in OpenAlex.
- CX3CL1/CX3CR1 signaling in spinal metastasis: mechanisms and translational opportunities.Clinical & experimental metastasis · 2026Review
- Chemokine-chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming.Chinese medical journal · 2026Review
- Pathophysiological Roles of the CX3CL1-CX3CR1 Axis in Renal Disease, Cardiovascular Disease, and Cancer.International journal of molecular sciences · 2025Review
- Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.The Journal of experimental medicine · 2025Article
- The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer.Neoplasia (New York, N.Y.) · 2025Article
- Immunotherapy in advanced,Therapeutic advances in medical oncology · 2025Review
- Biological and prognostic insights into the prostaglandin D2 signaling axis in lung adenocarcinoma.Frontiers in pharmacology · 2025Article
- KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.British journal of cancer · 2024Article
- Fractalkine in Health and Disease.International journal of molecular sciences · 2024Review
- CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.International journal of molecular sciences · 2024Review
- Neoadjuvant radiotherapy in ERFrontiers in immunology · 2024Article
- CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity.Frontiers in immunology · 2024Article
- Article
- Exploring the role of miR-200 family in regulating CX3CR1 and CXCR1 in lung adenocarcinoma tumor microenvironment: implications for therapeutic intervention.Scientific reports · 2023Article
- Article
- A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1).Frontiers in genetics · 2023Article
- Review
- Tertiary Lymphoid Structures and Chemokine Landscape in Virus-Positive and Virus-Negative Merkel Cell Carcinoma.Frontiers in oncology · 2022Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines are a family of small cytokines, which are signalling proteins secreted by cells. The principal role of chemokines is to serve as chemoattractants to guide the migration of their target cells. Chemokine C-X3-C motif ligand 1 (CX3CL1) is a protein-coding gene of fractalkine, which serves as a ligand for chemokine C-X3-C motif receptor 1 (CX3CR1) and integrins. However, the roles of CX3CL1 in different pathological types of lung cancer remain poorly understood. The present study aimed to investigate the potential clinical and biological function of CX3CL1 mRNA expression in patients with lung cancer. In the present study, lung cancer data obtained from the Gene Expression Omnibus database and The Cancer Genome Atlas were downloaded and analysed, and the results demonstrated that an increased CX3CL1 mRNA expression in tumour tissues from lung adenocarcinoma (LUAD) was associated with improved overall survival. However, no significant association was identified between CX3CL1 expression and the prognosis of lung squamous cell carcinoma (LUSC). Furthermore, the genes whose expression levels were correlated with CX3CL1 expression were subjected to enrichment analysis, and the results for the LUAD data demonstrated that the most significant biological processes included 'positive regulation of cell adhesion', 'leukocyte cell-cell adhesion', 'leukocyte migration' and 'T cell activation', whereas, the important highly ranked pathways included 'cell adhesion molecules (CAMs)', 'leukocyte transendothelial migration' and 'natural killer cell-mediated cytotoxicity'. However, in the patients with LUSC, the genes that were highly correlated with CX3CL1 were not enriched for any biological processes or signalling pathways. Based on the data of the present study, it was hypothesised that CX3CL1 may serve as a prognostic marker for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.